Reference
Gantner P, et al. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: A cohort study. Scandinavian Journal of Infectious Diseases 46: 838-845, No. 12, 2014. Available from: URL: http://doi.org/10.3109/00365548.2014.947318 - France
Rights and permissions
About this article
Cite this article
Atazanavir/raltegravir. Reactions Weekly 1572, 34 (2015). https://doi.org/10.1007/s40278-015-1059-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-015-1059-y